A Look At WuXi Biologics (SEHK:2269) Valuation After Securing ISO 13485:2016 Certification

Simply Wall St.04-17

WuXi Biologics (Cayman) (SEHK:2269) recently obtained ISO 13485:2016 certification for its medical device quality management system with zero non conformities, an event that draws attention to how ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2628243499?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000","is_english":true,"pubTime":"2026-04-17 01:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2628243499","market":"nz","top_or_hot":-1,"title":"A Look At WuXi Biologics (SEHK:2269) Valuation After Securing ISO 13485:2016 Certification","media":"Simply Wall St.","content":"<div>\n<p>WuXi Biologics (Cayman) (SEHK:2269) recently obtained ISO 13485:2016 certification for its medical device quality management system with zero non conformities, an event that draws attention to how ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2269/wuxi-biologics-cayman-shares/news/a-look-at-wuxi-biologics-sehk2269-valuation-after-securing-i\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At WuXi Biologics (SEHK:2269) Valuation After Securing ISO 13485:2016 Certification</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At WuXi Biologics (SEHK:2269) Valuation After Securing ISO 13485:2016 Certification\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-17 01:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2269/wuxi-biologics-cayman-shares/news/a-look-at-wuxi-biologics-sehk2269-valuation-after-securing-i><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>WuXi Biologics (Cayman) (SEHK:2269) recently obtained ISO 13485:2016 certification for its medical device quality management system with zero non conformities, an event that draws attention to how ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2269/wuxi-biologics-cayman-shares/news/a-look-at-wuxi-biologics-sehk2269-valuation-after-securing-i\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ISO","symbol_name":"IsoPlexis Corp.","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2269/wuxi-biologics-cayman-shares/news/a-look-at-wuxi-biologics-sehk2269-valuation-after-securing-i","article_id":"2628243499","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2269/wuxi-biologics-cayman-shares/news/a-look-at-wuxi-biologics-sehk2269-valuation-after-securing-i","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2628243499","pubTimestamp":1776359316,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"WuXi Biologics (Cayman) (SEHK:2269) recently obtained ISO 13485:2016 certification for its medical device quality management system with zero non conformities, an event that draws attention to how quality and compliance feed into its equity story.\nSee our latest analysis for WuXi Biologics (Cayman).\nThe ISO 13485:2016 win comes as the share price trades at HK$37.18, with a 1 month share price return of 6.41% and a year to date share price return of 14.26%. Over a longer horizon, the 1 year...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"ISO":"IsoPlexis Corp.","BK1589":"北水核心资产","LU0417516902.SGD":"Allianz China Equity Cl AT Acc SGD","LU0823426480.USD":"法巴中国股票经典Dis","LU0043850808.USD":"HSBC GIF ASIA EX JAPAN EQUITY \"AD\" INC","LU0588546209.SGD":"Eastspring Investments - China Equity Fund AS SGD","LU1242518931.SGD":"Fullerton Lux Funds - Asia Absolute Alpha A Acc SGD","LU0417516738.SGD":"Allianz Hong Kong Equity AT Acc SGD","LU0348735423.USD":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC","LU0856984785.SGD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED GROWTH \"ACH\" (SGDHDG) ACC","LU1880383366.USD":"东方汇理中国股票基金 A2 (C)","BK1141":"生命科学工具和服务","LU0359201612.USD":"贝莱德中国基金A2","SG9999002562.SGD":"LionGlobal Asia Pacific SGD","BK1576":"医药外包概念","LU0051755006.USD":"摩根大通中国A (dist)","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","LU0979878070.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"A\" (USD) ACC","LU0516422366.SGD":"Fullerton Lux Funds - Asia Focus Equities A Acc SGD","LU1688375341.USD":"贝莱德中国灵活股票基金","SG9999002463.SGD":"LionGlobal China Growth SGD","LU0819121731.USD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED GROWTH \"AC\" (USD) ACC","LU0456846285.SGD":"JPMorgan Funds - Greater China A (acc) SGD","BK1610":"ETF&股票定投概念","LU1720050803.USD":"安联全方位中国股票基金","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","LU0572944931.SGD":"Janus Henderson Horizon China Opportunities A2 SGD","LU0181495838.USD":"施罗德新兴亚洲A Acc","LU0456827905.SGD":"JPMorgan Funds - China A (acc) SGD","BK4121":"生命科学工具和服务","LU0140636845.USD":"施罗德大中华区股票A Acc","LU0516423091.SGD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (SGD) ACC","LU0348825331.USD":"ALLIANZ CHINA EQUITY \"A\" (USD) INC","LU0052750758.USD":"富兰克林中国基金A Acc","LU0320764599.SGD":"FTIF - Templeton China A Acc SGD","IE00B0JY6N72.USD":"PINEBRIDGE GLOBAL EMERGING MARKETS FOCUS EQUITY \"A\" (USD) ACC","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","LU0708995583.HKD":"TEMPLETON CHINA \"A\" (HKD) ACC","LU2039709279.SGD":"MANULIFE GF DRAGON GROWTH \"AA\" (SGDHDG) INC","02269":"药明生物","LU0823426308.USD":"法巴中国股票基金","LU3063872942.SGD":"FULLERTON LUX FUNDS ASIA EQUITIES \"I\" (SGD) ACC","LU0516422440.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"A\" (USD) ACC","LU1242518857.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"I\" (USD) ACC","BK1521":"挪威政府全球养老基金持仓","LU0327786744.USD":"Janus Henderson Horizon China Opportunities A2 USD","LU0039217434.USD":"HSBC GIF CHINESE EQUITY \"AD\" INC","LU0516423174.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (USD) ACC","LU0516422952.EUR":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (EUR) ACC","LU0307460666.USD":"EASTSPRING INVESTMENTS CHINA EQUITY \"A\" ACC"},"translate_title":"药明生物(SEHK：2269)获得ISO 13485：2016认证后的估值一览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ISO":1.5,"02269":0.9},"content_text":"WuXi Biologics (Cayman) (SEHK:2269) recently obtained ISO 13485:2016 certification for its medical device quality management system with zero non conformities, an event that draws attention to how quality and compliance feed into its equity story. See our latest analysis for WuXi Biologics (Cayman). The ISO 13485:2016 win comes as the share price trades at HK$37.18, with a 1 month share price return of 6.41% and a year to date share price return of 14.26%. Over a longer horizon, the 1 year total shareholder return of 81.37% contrasts with a 3 year total shareholder return decline of 28.71% and a 5 year total shareholder return decline of 66.26%, suggesting recent momentum is building off a weaker multi year record. If quality and compliance driven stories like WuXi Biologics interest you, it may be worth scanning a wider set of healthcare names using our screener for 125 healthcare AI stocks With WuXi Biologics trading at HK$37.18, an indicated intrinsic value gap of 38% and a 24% discount to the average analyst target, the key question is whether this is genuine mispricing or if markets are already incorporating expectations about future growth. AdvertisementMost Popular Narrative: 18% Undervalued At HK$37.18, the most followed narrative sees WuXi Biologics trading below an estimated fair value of HK$45.08, putting the focus firmly on whether its growth and margin profile can justify that gap.  The accelerated ramp in ADC (antibody-drug conjugates) and bispecific/multi-specific project wins, now making up over 40% of WuXi Biologics' portfolio and driving new, high-complexity business, positions the company as the partner of choice in these fast-growing biologics segments. This supports sustained backlog growth and provides strong visibility into higher late-stage and manufacturing revenues over the next 3-5 years.  Read the complete narrative. Want to see what revenue mix shift, margin assumptions, and future earnings multiple sit behind that HK$45.08 figure? The fair value hinges on a detailed blend of forecast growth, profitability, and discounting that is not obvious from the current share price alone. Result: Fair Value of HK$45.08 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, your thesis still hinges on geopolitical risk around China based CDMOs and high exposure to North America, where any regulatory shift or client loss could quickly change the story. Find out about the key risks to this WuXi Biologics (Cayman) narrative. Next Steps If this combination of optimism and risk gives you mixed feelings, consider acting promptly. Review the numbers yourself and weigh what matters most to you using 4 key rewards Looking for more investment ideas? If WuXi Biologics has sharpened your focus, do not stop here. Use the screener to widen your watchlist and spot opportunities you might otherwise miss.  Spot potential mispriced opportunities by scanning our set of companies trading below fair value using the 227 high quality undervalued stocks. Strengthen your portfolio’s foundation by filtering for businesses with robust finances through the solid balance sheet and fundamentals stocks screener (391 results). Seek under the radar opportunities that still show quality fundamentals by running the screener containing 575 high quality undiscovered gems.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if WuXi Biologics (Cayman) might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2628243499","isCrawlerRequest":true}